The NewCo model involves Chinese biotech firms establishing newly formed offshore entities (often Delaware or Cayman-based) to manage and develop their assets overseas, typically backed by international venture capital1
Mid-cap biotechs with validated clinical assets but limited global commercial infrastructure are the primary drivers of the NewCo surge, using it as a mainstream cross-border exit strategy1
Under the NewCo structure, innovators act as both licensors and significant minority shareholders, typically retaining 20% to 30% of equity upside while sharing development risks1
The NewCo model represents an evolution from product export to value export, allowing companies to retain greater research and development control while sharing long-term asset value through equity stakes2
Total licensing deal value from Chinese biotech firms reached a record $135.7 billion in 2025, more than doubling the $51.9 billion recorded in 20244
Average upfront payments for Chinese biotech deals increased from $102 million to $141 million between 2024 and 2025, indicating Chinese assets are no longer considered a bargain3
The NewCo model has increased market competition and made acquiring Chinese assets more complex and expensive for overseas companies, though it provides NewCos with direct overseas funding for clinical trials2
Major pharmaceutical companies including GSK, Merck, AstraZeneca, Eli Lilly, and AbbVie have become increasingly dependent on Chinese biotech pipelines, particularly in ADC and bispecific antibody sectors4
Sources:
1. https://www.morganlewis.com/pubs/2026/04/a-strategic-playbook-for-chinese-biotech-cross-border-deals-navigating-the-new-value-paradigm
2. https://www.yicaiglobal.com/news/chinese-biotech-firms-expand-beyond-licensing-toward-newco-model-experts-say
3. https://www.pharmavoice.com/news/china-biotech-recognize-value-bargain-over/814979/
4. https://www.globalxetfs.com.hk/research/china-biotech-update-from-fast-follower-to-global-leader/